Conversely, Sfrp5 antagonizes Wnt signaling, particularly the non-canonical pathway, by binding to Wnt ligands, thereby reducing inflammation and oxidative stress in adipose and vascular tissues 59,60, which may protect against metabolic syndrome and CAD 61,62. This evidence concerns the gene SFRP5 and metabolic syndrome.